Thomas A Zelniker

14PUBLICATIONS
48CO-AUTHORS
PharmacogenomicsCardiology (incl. cardiovascular diseases)Regenerative medicine (incl. stem cells)Predictive and prognostic markersCardiovascular medicine and haematology not elsewhere classified
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Jul 27, 2026
Cardioprotective properties of empagliflozin and other SGLT2 inhibitors.

|Apr 12, 2026
Design, rationale, and baseline characteristics of the dapagliflozin in haemodialysis (DAPA-HD) trial.

Thomas A Zelniker, Christopher Paschen, Christopher Mann

|Jan 27, 2026
Sex-Specific Differences in Patients with Hypertrophic Cardiomyopathy: A Cohort Study from Vienna.

Christopher Mann, Rodi Tosun, Shehroz Masood

|Mar 17, 2025
The Prognostic Implication of Late Gadolinium Enhancement Quantification and Syncope in Hypertrophic Cardiomyopathy.

Christopher Mann, Theresa M Dachs, Diana Gharib

|Feb 26, 2025
Circulating Autoantibodies Against Vasoactive Biomarkers Related to Orthostatic Intolerance in Long COVID Patients Compared to No-Long-COVID Populations: A Case-Control Study.

Emilie Han, Katrin Müller-Zlabinger, Ena Hasimbegovic

|Nov 24, 2023
Soluble ST2 in Heart Failure: A Clinical Role beyond B-Type Natriuretic Peptide.

Mauro Riccardi, Peder L Myhre, Thomas A Zelniker

Pageof 3

Frequent Collaborators

5 joint publications

Christian Hengstenberg

3 joint publications

Martin Riesenhuber

3 joint publications

Irene M Lang

2 joint publications

Felix Hofer